Delcath Systems Inc

NASDAQ:DCTHUnited States

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's products, HEPZATO KIT (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT) percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATO KIT is a drug/device combination product designed to administer high-dose chemotherapy directly into the liver while limiting systemic exposure and associated side effects. In Europe, the hepatic delivery system is a stand-alone medical device having the same device components as HEPZATO KIT, but without the melphalan hydrochloride and is approved for sale under the trade name CHEMOSAT. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).

Contact Information

Headquarters

566 Queensbury AvenueQUEENSBURY, NY, United States 12804

Phone

518-743-8892

Fax

212-489-2102

Executives

Independent Chairman of the Board

John Sylvester

Chief Executive Officer, Director

Gerard Michel

Chief Operating Officer

Martha Rook

Executive Vice President - Global Head of Operations

John Purpura

Senior Vice President - Finance, Chief Accounting Officer, Executive Officer

Sandra Pennell